AUTHORS
Hao Sun, MD, PhD, Shirong Liu, PhD2, Maria Luisa Guerrera, MD3, Amanda Kofides, MSc4, Nickolas Tsakmaklis5, John Hatcher, PhD6, Alberto Guijosa, MD7, Christopher Patterson, MBA, MPH8, Andrew Branagan, MD, PhD9, Lu-Gui Qiu, PhD10, Shayna Sarosiek, MD11, Jorge J Castillo, MD12, Zachary R Hunter, PhD13, Steven Treon, MD, PhD14
AFFILIATIONS
1 Bing Center for Waldenstrom Macroglobulinemia, Dana-Farber Cancer Institute, Boston, United States
2 Bing Center for Waldenstrom Macroglobulinemia, Dana-Farber Cancer Institute, Boston, United States
3 Bing Center for Waldenstrom Macroglobulinemia, Dana-Farber Cancer Institute, Boston, United States
4 Bing Center for Waldenstrom Macroglobulinemia, Dana-Farber Cancer Institute, Boston, United States
5 Bing Center for Waldenstrom Macroglobulinemia, Dana-Farber Cancer Institute, Boston, United States
6 Bing Center for Waldenstrom Macroglobulinemia, Dana-Farber Cancer Institute, Boston, United States
7 Bing Center for Waldenstrom Macroglobulinemia, Dana-Farber Cancer Institute, Boston, United States
8 Bing Center for Waldenstrom Macroglobulinemia, Dana-Farber Cancer Institute, Boston, United States
9 Division of Hematology and Oncology Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
10 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
11 Bing Center for Waldenstrom Macroglobulinemia, Dana-Farber Cancer Institute, Boston, United States
12 Bing Center for Waldenstrom Macroglobulinemia, Dana-Farber Cancer Institute, Boston, United States
13 Bing Center for Waldenstrom Macroglobulinemia, Dana-Farber Cancer Institute, Boston, United States
14 Bing Center for Waldenstrom Macroglobulinemia, Dana-Farber Cancer Institute, Boston, United States
ABSTRACT
Background: Waldenstrom macroglobulinemia (WM) is shaped by malignant lymphoplasmacytic cells and the bone marrow immune microenvironment, but the heterogeneity and tumor-supportive functions of myeloid cells remain poorly defined. We characterized monocyte states in WM and investigated their bidirectional interactions with malignant cells.
Methods: We performed single-cell RNA sequencing with paired B-cell receptor and T-cell receptor sequencing on bone marrow samples from 26 patients with newly diagnosed WM and 6 age-matched healthy donors (HDs). Seventeen patients subsequently received ibrutinib monotherapy in trial NCT02604511, with a median follow-up of 50 months. A CITE-seq dataset from 3 untreated patients with WM was analyzed to define monocytic myeloid-derived suppressor cell (M-MDSC) signatures. Subclustering, pathway enrichment, pseudotime, and ligand–receptor analyses were combined with direct and transwell coculture experiments using BCWM.1 and THP-1 cells, CCR1 inhibition, CD54 blockade, and flow cytometry.
Results: CD54⁺ classical monocytes (CD14⁺CD16⁻CD54⁺) were markedly expanded in WM but nearly absent in HDs, representing the immune population with the largest fold change, whereas CD54⁻ classical monocytes were reduced. WM classical monocytes showed increased inflammatory genes, including S100A8/9, IL1B, CXCL8, NFKB1, and NFKBIA; reduced anti-inflammatory regulators, including IL10, NT5E, and IL10RA; and attenuated MHC class II antigen-presentation genes. Multiple similarity analyses showed that WM classical monocytes more closely resembled CITE-seq-defined M-MDSCs than did HD monocytes.
Fine sub-clustering of classical monocytes further identified one CD54⁻ homeostatic classical monocyte population and four CD54⁺ classical monocyte states: PLXDC2⁺, IL1B⁺, IL1R2⁺, and LGALS1⁺. These states were associated with early activation, peak inflammation, post-inflammatory regulation, and immunosuppression, respectively. Pseudotime analysis defined a continuous trajectory progressing from CD54⁻ classical monocytes through the CD54⁺PLXDC2⁺, CD54⁺IL1B⁺, and CD54⁺IL1R2⁺ states, and ultimately to the CD54⁺LGALS1⁺ state.
Along this trajectory, inflammatory and suppressive genes such as AREG, S100A8/9, and LGALS1 progressively increased, whereas MHC class II genes, including HLA-DRA and HLA-DPA1, progressively decreased. FOXP1 and RUNX1 showed a U-shaped pattern, suggesting dynamic regulatory remodeling during monocyte-state transition.
In both direct and transwell coculture, BCWM.1 cells induced THP-1 cells to acquire a CD54⁺ phenotype with increased S100A8/9, IL-1β, HIF-1α, LGALS1, and CCR1 expression, recapitulating the inflammatory and immunosuppressive features observed in patient samples. Ligand–receptor analysis identified enhanced CCL3/4–CCR1 signaling from WM cells to classical monocytes, together with HMGB1–TLR2 and HMGB1–HAVCR2 interactions. CCR1 expression was highest in CD54⁺ classical monocytes among bone marrow cells, and pharmacologic CCR1 inhibition significantly reduced their induction, supporting a role for CCR1 in WM-associated monocyte reprogramming.
Reciprocally, ICAM1/CD54–IL2RA was among the strongest candidate interactions between classical monocytes and WM cells. Independent bulk RNA sequencing confirmed the expression of all three IL-2 receptor subunits, IL2RA, IL2RB, and IL2RG, in WM cells. Among all cell types, malignant B cells showed the second-highest IL2RA expression, exceeded only by regulatory T cells. Functionally, exogenous IL-2 increased WM cell proliferation in a dose-dependent manner, demonstrating that WM cells are responsive to IL-2. Together, these findings suggest a potential association between CD54⁺ classical monocytes and an IL-2-responsive tumor-cell phenotype in WM.
Conclusions: WM contains a previously unrecognized continuum of CD54⁺ classical monocyte states characterized by inflammation, impaired antigen presentation, and an M-MDSC-like phenotype. WM-derived CCL3/4–CCR1 signaling promotes the development of CD54⁺ monocytes. In parallel, WM cells express all three IL-2 receptor subunits and exhibit dose-dependent proliferative responses to exogenous IL-2. CCR1-mediated monocyte reprogramming and its possible connection to IL-2-dependent tumor support therefore represent potentially targetable features of the WM immune microenvironment.
DISCLOSURES
Hao Sun, MD, PhD: No relevant conflicts of interest to declare.